Corporate practice of medicine in 2026: the map MSOs operate on

The corporate practice of medicine doctrine says a corporation cannot practice medicine or employ physicians to do it. The workaround is older than most of the people using it: a physician-owned professional corporation holds the licenses, a management services organization holds everything else, and a management agreement moves the money. Regulators tolerated the arrangement for decades because the alternative was unwinding half of American healthcare delivery.

What changed is that legislatures stopped regulating the paper and started regulating the substance: who controls the practice, and where the money goes. The wave that started in 2025 is the most active CPOM period in a generation, and it is aimed at the MSO.

The wave, dated

Oregon, SB 951. The strictest statute in the country. MSOs and their affiliates may not hold majority ownership in the professional entity, exercise proxy or share-transfer control, or hold decision authority over clinical staffing, compensation, coding, billing policy, pricing, or payer contracting. New arrangements had to comply by January 1, 2026; existing ones have until January 1, 2029. Non-competes and gag clauses voided immediately. The 2026 HB 3410 amendments narrowed the exemptions rather than the rule.

California, SB 351 and AB 1415. Effective January 1, 2026. SB 351 codifies the control line: no MSO influence over clinical decisions, scheduling, records, billing and coding decisions, or payer contracting, with non-competes and gag clauses unenforceable. AB 1415 puts MSOs and their investors inside OHCA's 90-day transaction notice regime, with financial disclosure authority behind it.

Massachusetts, H.5159. Effective 2025. Pulls private equity, REITs, and MSOs into the state's transaction notification and cost oversight machinery, with expanded false claims exposure for investors. Maine expanded its transaction reporting the same year.

Indiana, SB 219. Healthcare-specific merger filings to the state attorney general, tracking federal HSR filings, for transactions after June 30, 2026.

The pending file. Vermont's H.583 would restrict MSO structures and debt-financed dividends outright. Pennsylvania's HB 2115 would add 120-day notice. Rhode Island, Hawaii, and Washington have bills moving, and New York's budget proposal would expand its material transactions law with post-close reporting. Not all of these pass. Enough will.

What the new laws actually regulate

Strip the drafting differences and every statute lands on the same two clauses.

Control: the recurring list is payer contracting, billing and coding decisions, clinical staffing and compensation, scheduling, and records. These are the services a full-scope MSO has sold for thirty years, which is why "we technically comply because the PC signs everything" no longer works. The statutes reach indirect control, de facto control, and in Oregon's case the ownership mechanics behind control.

Money: disclosure regimes in California and Massachusetts, plus the transaction filings elsewhere, all put the management services agreement in front of a regulator. The fee, long priced by habit, becomes evidence. A fee that scales with clinical revenue argues the MSO holds exactly the economic interest in volume the control provisions prohibit. A cost-plus fee with support behind it argues the opposite.

Three regimes, one playbook

The map now sorts into three tiers. Strong-CPOM states with new statutes: Oregon, California, Massachusetts, New York by long practice, with company arriving each session. Traditional CPOM states enforcing older doctrine: Texas, New Jersey, and roughly two dozen others, where the friendly-PC model works but percentage fees and control terms draw fee-splitting scrutiny. Permissive states, a shrinking set, where the MSO question is mostly a federal and payer question.

Whatever the tier, the fix is the same, because a platform built for the strictest state it touches does not restructure twice. Scope the MSA to services the statutes leave on the MSO side. Price them at cost plus a market markup, median 22.7% on cost. Keep the FMV file current, since every disclosure regime on the map can ask for it, and every buyer's diligence team already does.

Common questions

What is the corporate practice of medicine? A state-law doctrine barring corporations from practicing medicine or employing physicians to practice. It is why MSO structures separate the licensed practice from its business operations.

Which states restrict MSOs most? Oregon under SB 951, followed by California under SB 351, with New York's fee-splitting rules the strictest on fee structure specifically. Massachusetts leads on transaction oversight.

Is the friendly PC model dead? No, but the version where the MSO controls billing, payer contracts, and clinical staffing is dead in Oregon and California, and the version priced as a percentage of revenue was never alive in New York or Illinois.

Do the new laws apply to existing MSOs? Mostly yes. California's rules reach existing arrangements now; Oregon gives legacy structures until January 1, 2029; disclosure regimes apply at the next transaction.

Sources and method

Statutes and bills as of September 2026: Oregon SB 951 and HB 3410, California SB 351 and AB 1415, Massachusetts H.5159, Indiana SB 219, and pending measures in Vermont, Pennsylvania, Rhode Island, Hawaii, Washington, and New York, per current health-law trackers and firm analyses. The legislative map moves monthly; verify current status before relying on any entry. Benchmark figures are free-tier medians from the MSOs module.

This article is general regulatory and market information, not legal advice. Consult healthcare counsel for any specific arrangement or state.